Welcome to our dedicated page for Zevra Therapeutics news (Ticker: $ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zevra Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zevra Therapeutics's position in the market.
Rhea-AI Summary
Zevra Therapeutics, Inc. announces FDA extension of arimoclomol NDA review for Niemann-Pick disease type C with a new PDUFA action date of September 21, 2024. The company remains optimistic about the potential of arimoclomol to help patients despite the delay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.15%
Tags
-
Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) announces Neil F. McFarlane, President and CEO, will present at investor conferences in March 2024. The company will participate in TD Cowen 44th Annual Health Care Conference and 36th Annual ROTH Conference. The live webcasts will be available on Zevra's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
-
News
Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The company's management team will also be available for one-on-one investor meetings. The live webcast will be accessible on the company's website, and the archived presentation will be available thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
Rhea-AI Summary
Zevra Therapeutics, Inc. appoints Alvin Shih, MD, MBA, to its Board of Directors. Dr. Shih brings extensive experience in biotechnology leadership and rare disease therapeutics development. He has held leadership roles at various biotechnology companies and has a strong background in drug development for rare diseases. Zevra's Board and management team express confidence in Dr. Shih's ability to contribute to the advancement of the company's therapeutic portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
-
Rhea-AI Summary
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has announced that the U.S. FDA has assigned a PDUFA action date of June 21, 2024, for the resubmission of the New Drug Application (NDA) for arimoclomol as a first-in-class treatment for Niemann-Pick disease type C. The resubmission addresses concerns previously raised in the FDA's complete response letter and includes additional evidence supporting trial metrics and data from multiple additional studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
-
Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) appoints Dr. Adrian Quartel, M.D., FFPM, as Chief Medical Officer, bringing extensive experience in the pharmaceutical industry. Dr. Quartel's appointment follows Zevra's recent acquisition of Acer Therapeutics, expanding their rare disease portfolio. The company aims to develop and commercialize therapies for rare and ultra-rare diseases with significant unmet needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
Rhea-AI Summary
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) resubmits NDA for arimoclomol, an investigational therapeutic candidate for Niemann-Pick disease type C (NPC) to the FDA. The NDA is expected to be classified as a Class II submission, subject to a review period within six months. The resubmission includes additional evidence, new data, and results from multiple non-clinical studies and early access programs, suggesting arimoclomol's potential to reduce the progression of NPC. Arimoclomol has been evaluated in 21 studies across Phase 1, 2, and 3 trials, showing promise in treating NPC and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
-
Rhea-AI Summary
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) completes acquisition of Acer Therapeutics Inc., propelling the company into the commercial stage with OLPRUVA®, an FDA-approved treatment for urea cycle disorders (UCDs). The settlement of Acer’s warrant obligations diversifies Zevra's revenue and adds a quality healthcare investor to its shareholder base. The acquisition includes 2.96 million shares of Zevra stock and contingent value rights (CVRs) worth up to $76 million. Zevra also purchased Acer’s senior secured debt for $28.5 million, further strengthening its position in developing and commercializing treatments for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
-
Rhea-AI Summary
Zevra Therapeutics, Inc. reported net revenue of $2.9M for Q3 2023 and ended the quarter with $83.4M in cash. The company is on track to resubmit the arimoclomol NDA by the end of the year. The proposed acquisition of Acer Therapeutics is expected to close in Q4 2023, diversifying Zevra's revenue with FDA-approved OLPRUVA® for urea cycle disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
Rhea-AI Summary
Zevra Therapeutics, Inc. will host a conference call and live audio webcast on November 7, 2023, to review its corporate and financial results for Q3 2023. The webcast will be accessible via the Investor Relations section of the company's website. The conference call dial-in information is provided. An archive of the webcast will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
Zevra Therapeutics, Inc.
Nasdaq:ZVRA
ZVRA Rankings
ZVRA Stock Data
215.95M
36.09M
8.08%
29.7%
5.38%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
CELEBRATION
About ZVRA
kempharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (nces) to treat serious medical conditions through its proprietary and broadly applicable ligand activated therapy (lat) approach. the company utilizes its lat technology to generate improved prodrug versions of fda approved drugs in the high needs areas of pain, adhd and other cns diseases.